| Literature DB >> 36110504 |
Kenechi O Nnamani1, Chioma P Nnamani2, Kenechukwu K Iloh3, Iloduba N Aghanya4, Simon N Ushie4, Ogochukwu C Ofiaeli1, Chijioke E Ezeudu1, Chinyere U Onubogu1, Ebelechukwu F Ugochukwu1, Comfort N Akujobi4, Clement C Ezechukwu1.
Abstract
Background: Neonatal sepsis (NNS) in developing countries continues to be a diagnostic and management challenge due to the delays in identifying the aetiologic pathogens and antibiograms. Aim: To determine the predominant bacterial isolates, antibiotic susceptibility pattern and outcomes of blood culture proven sepsis in neonates. Methodology: A hospital-based cross-sectional study of 120 neonates admitted into the Special Care Baby Unit (SCBU) of Nnamdi Azikiwe University Teaching Hospital Nnewi with clinical features suggestive of sepsis. A semi-structured questionnaire and proforma were used to record neonatal, maternal and laboratory information. Blood specimens were collected for aerobic culture using Bactenecin (BACTEC)-Ped plus culture system. Antibiotic susceptibility testing was performed using the Kirby Bauer disc diffusion method. Data obtained were analysed using SPSS version 23.0. p value < 0.05 was considered as significant.Entities:
Keywords: Nigeria; antibiogram; bacterial isolate; neonatal sepsis; outcomes
Year: 2022 PMID: 36110504 PMCID: PMC9468700 DOI: 10.1177/20499361221122479
Source DB: PubMed Journal: Ther Adv Infect Dis ISSN: 2049-9361
General characteristics of the study population.
| Variable | Frequency ( | Percentage (%) |
|---|---|---|
| Sex | ||
| Male | 68 | 56.7 |
| Female | 52 | 43.3 |
| Social class | ||
| I | 4 | 3.3 |
| II | 13 | 10.9 |
| III | 39 | 32.5 |
| IV | 64 | 53.3 |
| Maturity | ||
| Preterm < 37 weeks GA | 43 | 35.8 |
| Term > 37–42 weeks GA | 77 | 64.2 |
| Mode of delivery | ||
| Spontaneous vaginal delivery | 90 | 75.0 |
| Assisted vaginal delivery | 2 | 1.7 |
| Caesarean section | 28 | 23.3 |
| Resuscitation at delivery | ||
| Yes | 59 | 49.2 |
| No | 61 | 50.8 |
| Birth weight | ||
| Low < 2500 g | 47 | 39.1 |
| Normal 2500–3999 g | 65 | 54.2 |
| High ⩾ 4000 g | 8 | 6.7 |
| Mean ± (SD) | 2610.83 ± 913.20 | |
Class I and II, Upper Socioeconomic class; Class III, Middle Socioeconomic class; Class IV, Lower Socioeconomic class; GA, gestational age; IOR, interquartile range; SD, standard deviation.
Association between participants’ characteristics and NNS.
| Host factors | NNS | Test statistic | |||
|---|---|---|---|---|---|
| Culture positive | Culture negative | Total | |||
| Sex | |||||
| Male | 17 (25.0) | 51 (75.0) | 68 (100.0) | 0.000
| 1.000 |
| Female | 13 (25.0) | 39 (75.0) | 52 (100.0) | ||
| Maturity | |||||
| Preterm < 37 weeks | 5 (11.6) | 38 (88.4) | 43 (100.0) | 6.391
| 0.011 |
| Term 37–42 weeks | 25 (32.5) | 52 (67.5) | 77 (100.0) | ||
| Place of Delivery | |||||
| Inborn | 1 (3.3) | 15 (16.7) | 16 (100) | 3.461
| 0.070 |
| Out born | 29 (96.7) | 75 (83.3) | 104 (100) | ||
| Birth weight | |||||
| Low (<2500 g) | 10 (19.3) | 42 (80.7) | 52 (100.0) | 1.673
| 0.432 |
| Normal (2500–3999 g) | 19 (29.7) | 45 (70.3) | 64 (100.0) | ||
| High (⩾4000 g) | 1 (75.0) | 3 (25.0) | 8 (100.0) | ||
NNS, neonatal sepsis.
Chi-square.
Fischer’s Exact.
Statistically significant.
Distribution of isolates by types of NNS.
| Organisms | EONS ( | LONS ( | Total | ||
|---|---|---|---|---|---|
| Term (%) | Preterm (%) | Term (%) | Preterm (%) | ||
|
| 4 (13.3) | 2 (6.7) | 6 (20.0) | 1 (3.3) | 13 (43.3) |
|
| 2 (6.7) | 0 | 2 (6.7) | 1 (3.3) | 5 (16.7) |
|
| 2 (6.7) | 1 (3.3) | 0 | 0 | 3 (10.0) |
|
| 1 (3.3) | 0 | 2 (6.7) | 0 | 3 (10.0) |
|
| 1 (3.3) | 0 | 1 (3.3) | 0 | 2 (6.7) |
|
| 0 | 0 | 2 (6.7) | 0 | 2 (6.7) |
|
| 1 (3.3) | 0 | 0 | 0 | 1 (3.3) |
|
| 1 (3.3) | 0 | 0 | 0 | 1 (3.3) |
|
| 12 | 3 | 13 | 2 | 30 (100.0) |
EONS, early-onset NNS; LONS, late-onset NNS.
Outcome of NNS by organism.
| Isolate | Outcome | Total | |
|---|---|---|---|
| Discharged | Mortality | ||
|
| 13 (46.4) | 0 (0.0) | 13 (43.3) |
| Coagulase-negative | 5 (17.9) | 0 (0.0) | 5 (16.7) |
|
| 2 (7.1) | 1 (50.0) | 3 (10.0) |
| 3 (10.7) | 0 (0.0) | 3 (10.0) | |
| 1 (3.6) | 1 (50.0) | 2 (6.7) | |
|
| 2 (7.1) | 0 (0.0) | 2 (6.7) |
|
| 1 (3.6) | 0 (0.0) | 1 (3.3) |
|
| 1 (3.6) | 0 (0.0) | 1 (3.3) |
| Total | 28 (100.0) | 2 (100.0) | 30(100.0) |
Antibiogram of the Gram-positive isolates.
| Isolates | Antibiotics (%) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MEM | CIP | CN | AMP | PEN | SXT | C | LEV | E | DA | FOX | VA | LZD | |
| Sensitive | 46.2 | 92.3 | 7.7 | 23.1 | 66.7 | 62.5 | 38.5 | 76.9 | 38.5 | 100 | 100 | ||
| Resistant | 53.8 | 7.7 | 92.3 | 76.9 | 33.3 | 37.5 | 61.5 | 23.1 | 61.5 | 0 | 0 | ||
| Coagulase-negative
| |||||||||||||
| Sensitive | 40.0 | 100 | 0 | 20 | 60 | 40 | 40 | 0 | 60 | 80 | 80 | ||
| Resistant | 60.0 | 0 | 100 | 80 | 40 | 60 | 60 | 100 | 40 | 20 | 20 | ||
| Sensitive | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Resistant | 100 | 100 | 100 | 100 | 100 | 100 | 100 | ||||||
AMP, ampicillin; C, chloramphenicol; CIP, ciprofloxacin; CN, gentamicin; DA, clindamycin; E, erythromycin; FOX, cefoxitin; LEV, levofloxacin; LZD, linezolid; MEM, meropenem; PEN, penicillin; SXT, sulfomethoxazole/trimethoprin; VA, vancomycin.
Antibiogram of the Gram-negative isolates.
| Isolates | Antibiotics (%) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MEM | FEP | CIP | AMC | CN | CXM | TZP | ETP | AMP | CAZ | CRO | AK | IPM | |
| Sensitive | 100 | 33.3 | 100 | 0 | 33.3 | 66.7 | 33.3 | 33.3 | 100 | 100 | |||
| Resistant | 0 | 66.7 | 0 | 100 | 66.7 | 33.3 | 66.7 | 66.7 | 0 | 0 | |||
| Sensitive | 66.7 | 33.3 | 100 | 0 | 33.3 | 33.3 | 66.7 | 66.7 | 0 | 33.3 | 33.3 | 100 | 100 |
| Resistant | 33.3 | 66.7 | 0 | 100 | 66.7 | 66.7 | 33.3 | 33.3 | 100 | 66.7 | 66.7 | 0 | 0 |
| Sensitive | 100 | 50 | 100 | 0 | 50 | 0 | 100 | 50 | 0 | 50 | 0 | 50 | 100 |
| Resistant | 0 | 50 | 0 | 100 | 50 | 100 | 0 | 50 | 100 | 50 | 100 | 50 | 0 |
| Sensitive | 100 | 0 | 100 | 100 | 0 | 100 | 100 | ||||||
| Resistant | 0 | 100 | 0 | 0 | 100 | 0 | 0 | ||||||
| Sensitive | 100 | 100 | 100 | 0 | 100 | 0 | 100 | 100 | 0 | 100 | 100 | 100 | 100 |
| Resistant | 0 | 0 | 0 | 100 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | 0 | 0 |
AK, amikacin; AMC, amoxicillin–clavulanate; AMP, ampicillin; CAZ, ceftazidime; CIP, ciprofloxacin; CN, gentamicin; CRO, ceftriaxone; CXM, cefuroxime; ETP, ertapenem; FEP, cefepime; IPM, imipenem; MEM, meropenem; TZP, piperacillin–tazobactam.